Cover Image
市場調查報告書

白細胞介素1 (IL1):開發中產品分析

Interleukin 1 (IL1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 516031
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素1 (IL1):開發中產品分析 Interleukin 1 (IL1) - Pipeline Review, H2 2017
出版日期: 2017年11月21日 內容資訊: 英文 106 Pages
簡介

本報告提供以白細胞介素1 (IL1)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供包含最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素1 (IL1);概要

白細胞介素 1 (IL1);治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關的開發中產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Anacor Pharmaceuticals Inc
  • Apexigen Inc
  • Cell Medica Ltd
  • Exicure Inc
  • Immune Response BioPharma Inc
  • Novartis AG
  • Omnitura Therapeutics Inc
  • Opsona Therapeutics Ltd
  • Optimum Therapeutics LLC
  • Orphit SAS
  • Peptinov SAS
  • R Pharm
  • Regeneron Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • TWi Biotechnology Inc
  • XBiotech Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1151TDB

Summary:

Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.

Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 2, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Metabolic Disorders, Oncology, Cardiovascular, Dermatology, Central Nervous System, Gastrointestinal, Genetic Disorders, Ear Nose Throat Disorders and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Epidermolysis Bullosa, Inflammation, Non-Small Cell Lung Cancer, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Rheumatoid Arthritis, Type 2 Diabetes, Acne Vulgaris, Alzheimer's Disease, Autoimmune Disorders, Bladder Cancer, Bullous Pemphigoid, Cachexia, Cardiovascular Risk Factors, Cervical Cancer, Colorectal Cancer, Dermatological Disorders, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Inflammatory Bowel Disease, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Osteoarthritis, Ovarian Cancer, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Sarcoidosis, Skin Inflammation, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).

The latest report Interleukin 1 (IL1) - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
  • The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 1 (IL1) - Overview
    • Interleukin 1 (IL1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Interleukin 1 (IL1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Apexigen Inc
    • Exicure Inc
    • Immune Response BioPharma Inc
    • Moderna Therapeutics Inc
    • Novartis AG
    • Omnitura Therapeutics Inc
    • Opsona Therapeutics Ltd
    • Optimum Therapeutics LLC
    • Orphit SAS
    • Peptinov SAS
    • Pfizer Inc
    • R Pharm
    • Regeneron Pharmaceuticals Inc
    • Spherium Biomed SL
    • Swedish Orphan Biovitrum AB
    • XBiotech Inc
  • Interleukin 1 (IL1) - Drug Profiles
    • ABT-981 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AC-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-4161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-2752 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMN-54 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PPV-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rilonacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOBI-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-15008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • suramin hexasodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Xilonix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ymalzen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 1 (IL1) - Dormant Products
  • Interleukin 1 (IL1) - Discontinued Products
  • Interleukin 1 (IL1) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 03, 2017: XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
      • Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting
      • Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
      • Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
      • Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
      • Sep 27, 2017: Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research
      • Sep 15, 2017: Refusal of the marketing authorization for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech
      • Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
      • Aug 27, 2017: Anti-inflammatory drug could reduce risk of second heart attack
      • Aug 27, 2017: Anti-Inflammatory Therapy Cuts Risk of Lung Cancer
      • Aug 27, 2017: Inflammatory Hypothesis Confirmed: Reducing Inflammation Without Lowering Cholesterol Cuts Risk of Cardiovascular Events
      • Aug 27, 2017: Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
      • Aug 27, 2017: Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
      • Aug 07, 2017: Novartis's Ilaris Rejects For Use Within NHS Scotland
      • Jun 22, 2017: Novartis Phase III study shows ACZ885 reduces cardiovascular risk in people who survived a heart attack
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AbbVie Inc, H2 2017
  • Pipeline by Apexigen Inc, H2 2017
  • Pipeline by Exicure Inc, H2 2017
  • Pipeline by Immune Response BioPharma Inc, H2 2017
  • Pipeline by Moderna Therapeutics Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Omnitura Therapeutics Inc, H2 2017
  • Pipeline by Opsona Therapeutics Ltd, H2 2017
  • Pipeline by Optimum Therapeutics LLC, H2 2017
  • Pipeline by Orphit SAS, H2 2017
  • Pipeline by Peptinov SAS, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by R Pharm, H2 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Pipeline by Spherium Biomed SL, H2 2017
  • Pipeline by Swedish Orphan Biovitrum AB, H2 2017
  • Pipeline by XBiotech Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Dormant Products, H2 2017 (Contd..4), H2 2017
  • Discontinued Products, H2 2017
  • Discontinued Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017 (Contd..2), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top